Tirzepatide has been in development since at least 2016, when Eli Lilly filed its investigational new drug application with the FDA. It first reached patients as an approved medication on May 13, 2022, when the FDA cleared it under the brand name Mounjaro for type 2 diabetes. So depending on how you count, the drug has been around for roughly 8 to 9 years in some form, but only about 3 years as something you can actually get prescribed.
From Lab to First Human Trials
Eli Lilly’s investigational new drug application for tirzepatide became effective on April 28, 2016. That’s the date the FDA gave the green light for human testing to begin. Before that, researchers had been working on the molecule’s design, building it around a concept that was genuinely new: a single drug that activates two gut hormone receptors instead of one.
Tirzepatide is built on the backbone of GIP, a natural hormone your body releases after eating. But it was engineered to also activate the GLP-1 receptor, the same target that drugs like semaglutide (Ozempic, Wegovy) hit. The key difference is that tirzepatide interacts with the GLP-1 receptor in an unusual way. Its binding is about fivefold weaker than the body’s own GLP-1, but this actually works in its favor. It triggers the receptor’s signaling without wearing it out as quickly, a property researchers call “reduced receptor desensitization.” The practical result is that the receptor stays responsive longer.
The Clinical Trial Timeline
Tirzepatide went through two major trial programs before reaching the market. The SURPASS trials tested it for type 2 diabetes, and the SURMOUNT trials tested it for weight loss in people without diabetes.
The SURPASS program began enrolling patients in late 2018. In SURPASS-4, for example, recruitment ran from November 2018 through December 2019. These trials compared tirzepatide against existing diabetes treatments. At 52 weeks, the highest dose of tirzepatide lowered A1C (a measure of average blood sugar over three months) by 2.58 percentage points, compared to 1.44 points for insulin glargine, a widely used long-acting insulin. That gap was significant enough to establish tirzepatide as clearly more effective at blood sugar control.
The SURMOUNT-1 trial, focused on weight loss, started enrolling on December 4, 2019, and measured results at 72 weeks. It tracked the percentage of participants hitting meaningful weight loss milestones: 5%, 10%, 15%, and 20% of their body weight. The results from this program ultimately supported a second FDA approval specifically for obesity.
FDA Approvals: 2022 and 2023
The first FDA approval came on May 13, 2022, when tirzepatide was cleared as Mounjaro for adults with type 2 diabetes. This made it the first dual-receptor drug of its kind to reach the U.S. market.
A year and a half later, on November 8, 2023, the FDA approved a second version of tirzepatide under the brand name Zepbound, this time specifically for chronic weight management. Zepbound was approved for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition like high blood pressure or high cholesterol. Both approvals specify that the drug should be used alongside diet changes and increased physical activity.
How It Compares to Semaglutide’s Timeline
For context, semaglutide (the active ingredient in Ozempic and Wegovy) was approved for type 2 diabetes in December 2017, about four and a half years before tirzepatide’s diabetes approval. Semaglutide’s weight management version, Wegovy, was approved in June 2021, roughly two and a half years before Zepbound. Tirzepatide is the newer drug in both categories, which partly explains why long-term safety data is still accumulating compared to its more established competitor.
Availability Outside the U.S.
The European Medicines Agency authorized Mounjaro on September 15, 2022, about four months after the U.S. approval. Rollout across individual European countries has varied, with some nations making it available quickly and others taking longer due to pricing negotiations and reimbursement decisions. In many parts of the world, tirzepatide is still relatively new or not yet available at all, which means the drug’s global presence is still expanding even now.
A Quick Timeline Summary
- April 2016: Eli Lilly’s investigational application goes active, human trials begin
- Late 2018: SURPASS diabetes trials start enrolling patients
- December 2019: SURMOUNT weight loss trials begin
- May 2022: FDA approves Mounjaro for type 2 diabetes
- September 2022: European Medicines Agency approves Mounjaro
- November 2023: FDA approves Zepbound for chronic weight management
From first-in-human testing to its current status as one of the most talked-about medications in the world, tirzepatide’s journey has spanned about nine years. Its time as an available prescription drug is much shorter, just three years for diabetes and under two years for weight management.